1 / 28

VHPB - Malta 22-23 October 2001

VHPB - Malta 22-23 October 2001. Summary conclusions: 1: Generalizations 2: Drawbacks, concerns and issues 3: Data and information . Goals of vaccine programmes. Prevention and control of disease, also eradication/elimination of pathogens Successes: eradication of smallpox

jennis
Download Presentation

VHPB - Malta 22-23 October 2001

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. VHPB - Malta 22-23 October 2001 Summary conclusions: 1: Generalizations 2: Drawbacks, concerns and issues 3: Data and information

  2. Goals of vaccine programmes • Prevention and control of disease, also eradication/elimination of pathogens • Successes: • eradication of smallpox • progress towards eradication of poliomyelitis, measles, and other disease • progress towards control of hepatitis B and Hib

  3. Vaccines • Safe and effective • most cost-effective medical and public health intervention against infectious diseases • hepatitis B vaccine: one of the safest and most effective vaccines ever developed • Development time reduced • Need for high-quality and affordable vaccines • Costs falling or can be reduced through cooperative bidding and other mechanisms

  4. Combined vaccines • Not new (e.g. influenza (AAB), OPV 1, 2 & 3, DTP, MMR, bacterial + viral vaccines, polyvalent vaccines) • Accelerated development and licensure, despite complexities • Safe and immunogenic • Effective - reducing disease and not altering pathogen circulation

  5. Combined vaccines - continued • Agreed principles for administration • e.g. acceptability of giving an extra dose of antigen • non-interchangeability of vaccines from different manufacturers • Quality assurance secured • accreditation of quality control laboratories (ISO system) • EU release certificate • Audits (EDQM, WHO - national regulatory authorities and manufacturers)

  6. Benefits • Simplified immunization programme implementation • increased acceptance, decreased global cost, increased disease control • decreased disease prevalence and burden • fewer health service visits and lower programme costs • increased vaccine coverage

  7. Benefits - continued • Reduced number of injections per visit and fewer injections given overall • reduced waste • increased safety - although limited role of combination vaccines in developing countries • less or no exposure to thiomersal • lower costs of storage, transport, cold chain (except developing countries)

  8. Benefits - continued • harmonization of antigens • ease of adding new antigens in existing programmes • data collection facilitated and documentation eased

  9. Drawbacks, concerns and issues • Wide variation in immunization schedules across Europe and compared with USA • national and federal approaches • different epidemiological patterns • issues of compulsory/obligatory and voluntary immunization • testing of each formulation for each immunization schedule in EU - ethical issues • school entry requirements

  10. Immunization schedules • history of attempts to harmonize • cross-roads in decision-making process • consequences for local production and global vaccine supply (e.g. DTP shortage and monovalent HB glut) • change in antigens (Pw  Pa, OPV  IPV) • maternal screening and routine immunization of newborns - unnecesary?

  11. Legislation and regulatory issues • Licensing, availability, usage - not the same • EU-wide licensing, but trials for each schedule • licensing of components, new formulations, increasingly complex with polyvalent Vs • post-marketing conditions • need to assess models for combined Vs

  12. Legislation and regulatory issues - continued • Legislation needs to be adapted to introduce new vaccines/antigens • inflexibility of programmes • Regulations for bidding and procurement • Compulsory immunization and legal consequences • legislation more powerful than education of physicians in driving immunization of schoolchildren

  13. Legal and regulatory issues • Thiomersal issue - lawsuits in litigious societies • manufacture of vaccines in industrialized countries for use in developing countries • role of national regulatory authorities in developing countries • flexibility of some countries (e.g. Italy)

  14. Clinical development and trials • Increasing complexity and cost • each component to be tested for safety and efficacy • number of arms increases exponentially with number of components, leading to trials with huge numbers of participants to test against different immunization schedules - “unethical” • Interference (immunological and chemical)

  15. Clinical development and trials - continued • Need to establish new minimum potency and protection levels • Need for new reference materials • Analysis of adverse reactions • Surrogate markers

  16. Financial issues • Prices • combined vs monovalent • premiums (e.g. Latin America) • trade off: fewer injections and side effects vs price • Who pays for vaccines and immunization? • Public/private sectors • Incentives (physicians/families) • Which vaccines are paid for by state? • Wide variations in EU, USA...

  17. Economic issues • Lower administrative costs • time of vaccinators • less pain for children, and parents save time and money • high willingness to pay for reduction from 4 to 3 and 2 to 1 injections • Complexity of health insurance. EU

  18. Funding mechanisms • Global Alliance for Vaccines and Immunization (GAVI) • Pan American Health Organization-type revolving funds • Other

  19. Hexavalent combined vaccines • Advantages: • increased compliance, • increased vaccine coverage, • facilitated data collection, • decreased costs compared to sum of separate vaccines (at least in Germany), • decreased storage and logistic requirements

  20. Hexavalent vaccines - continued • Quality issues (intermediates) • Efficacy • “Combination is more than mixing” • need for better/other markers of protection • Formulation issues • liquid, powder • Hib responses may be lower, but are protective (possibly related to pertussis component)

  21. Hexavalent vaccines - continued • Issues • how long does protection last? • few breakthrough infections - hepatitis B • memory immunity • variations in immunogenicity • reasons for reduced immunogenicity (ethnic differences in Sweden) • increased likelihood of adverse reactions? • limits to number of antigens?

  22. Manufacture and supply • Sole-source supply/source of antigens • Reliability of manufacturers to fulfil contracts or deliver • Procurement and bidding practices • Pre-qualification/availability • Manufacturers’ responses - strategic alliances (e.g. purchase of national companies)

  23. New data • “Combining is more than mixing” • Country updates - Europe is more than EU • Belgium, Finland, France, Germany, Israel, Italy, Lithuania, Switzerland, Turkey, USA • How anti-HBs protects • Genetic correlates of non-response to HB • strategies to overcome non-responsiveness • Production process • HB immunization schedules in Europe to be further updated

  24. Data needed • Vaccine production capacity • Manufacturers’ (general) future plans • Demand forecasting and data (national immunization programmes) • Disease burden/demographic data (e.g. births on developing countries) • Reasons for decreased immunogenicity of components in combined vaccines

  25. Data needed • Science • Reasons for decreased immunogenicity of components in combined vaccines • HB virus-binding site on hepatocytes • Mechanisms of action of anti-HBs • Mucosal immunity • Economic evaluation of combined vaccines

  26. Information and communication • Reasons for non-vaccination • insufficiency of information about diseases, vaccines and immunizations - parents’ view • missed appointments - common reason • doctors do not propose or recommend immunization • ideological opposition to vaccines - rare • Increase public sensitivity to safety issues • Campaigns needed • on benefits and safety of vaccines and combined vaccines • dispel myths (antigenic exhaustion/overload)

  27. Information and communication • Campaigns (cont) • targeted at • whole medical community - training in medical schools - particular focus on paediatricians, family physicians, practice nurses, health care workers • industry and professionals • parents • media (for balanced information) • Close communication and coordination between manufacturers and health authorities • WHO vaccine use database

  28. Conclusions • Combined vaccines with hepatitis B component are: • safe, effective, licensed, available, used, not (yet) cheap • present challenges and opportunities • added value • likely demand from parents, health-care workers and decision makers • German recommendation: “use whenever possible and applicable”

More Related